TFB 30: Entwicklung und klinische Evaluation eines neuen bispezifischen Moleküls zur Behandlung von Patienten mit Hodgkin-Lymphomen

点击翻译按钮获取中文摘要

For the first two years, the in vitro characterization of new human bispecific constructs targeting the CD30 antigen is planned. The constructs are based on the human anti-CD64 antibody H22 from Medarex Inc. and on an anti-CD30 antibody, that has yet to be defined. The preclincal evaluation of the bispecific construct will include also tests to determine the safety of its clinical application. All the scientific work will be done in cooperation with the companies medac GmbH and Medarex Inc. For the third year (2003), a clinical phase-I is planned, that could be followed by a phase-II study. The final aim of this project is the evaluation of a bispecific construct for the first-line treatment of Hodgkin´s disease in a phase-III study.